ASH 2022 | Key findings from the ASC4MORE study

Jorge Cortes • 23 Nov 2022

ASH 2022

ASC4MORE

Jorge Cortes, MD, Augusta University, Augusta, GA, describes the findings of the ASC4MORE study (NCT03578367). This study investigated the efficacy of asciminib with imatinib in comparison to continued imatinib or nilotinib in pre-treated patients with chronic myeloid leukemia (CML) who have not achieved a deep molecular response. The results of this study indicate that the addition of asciminib significantly improves molecular responses with minimal toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Gilead: Consultancy; Sun Pharma: Consultancy, Research Funding; Biopath Holdings Inc: Consultancy, Current equity holder in private company; Abbvie: Consultancy, Research Funding; Forma Therapeutic: Consultancy; Novartis: Consultancy, Honoraria, Research Funding.